BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, July 14, 2026
Home » Authors » Brady Huggett

Brady Huggett

Articles

ARTICLES

ImClone Says FDA Might Accept Erbitux BLA With No New Trials

Feb. 28, 2002
By Brady Huggett
ImClone Systems Inc., after being dragged to scandalous depths not often seen in the biotechnology sector, bobbed to the surface Wednesday following its meeting with the FDA concerning the cancer drug Erbitux. (BioWorld Today)
Read More

Biotech Products For Psoriasis Showing Encouraging Results

Feb. 26, 2002
By Brady Huggett
Although there remains no cure for psoriasis, presenters at the 60th annual meeting of the American Academy of Dermatology in New Orleans managed, at the very least, to provide hope for those burdened with the affliction. (BioWorld Today)
Read More

Biotech Products For Psoriasis Showing Encouraging Results

Feb. 26, 2002
By Brady Huggett
Although there remains no cure for psoriasis, presenters at the 60th annual meeting of the American Academy of Dermatology in New Orleans managed, at the very least, to provide hope for those burdened with the affliction. (BioWorld Today)
Read More

Immunex’s Enbrel Performs Well In Phase II Psoriasis Trial

Feb. 25, 2002
By Brady Huggett

Immunex’s Enbrel Performs Well In Phase II Psoriasis Trial

Feb. 25, 2002
By Brady Huggett

Orchid Raises $23M Through Public Offering Of 8M Shares

Feb. 22, 2002
By Brady Huggett

Orchid Raises $23M Through Public Offering Of 8M Shares

Feb. 22, 2002
By Brady Huggett

IDEC Gains Zevalin Approval For Non-Hodgkin’s Lymphoma

Feb. 21, 2002
By Brady Huggett
IDEC Pharmaceuticals Corp. received FDA approval of Zevalin to treat non-Hodgkin’s lymphoma and is poised to introduce the first radioimmunotherapy to the United States. (BioWorld Today)
Read More

Avant Dropping TP10 Following Phase II Failure; Stock Tumbles

Feb. 21, 2002
By Brady Huggett

IDEC Gains Zevalin Approval For Non-Hodgkin’s Lymphoma

Feb. 21, 2002
By Brady Huggett
IDEC Pharmaceuticals Corp. received FDA approval of Zevalin to treat non-Hodgkin’s lymphoma and is poised to introduce the first radioimmunotherapy to the United States. (BioWorld Today)
Read More
View All Articles by Brady Huggett

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 13, 2026.
  • Silhouette with keyhole

    FENS 2026: Next-gen biologics take on brain disease

    BioWorld
    Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
  • Wainua autoinjector

    Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

    BioWorld
    News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • NRF2 activators reported in Vailima Peninsula patent

    BioWorld Science
    Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing